GlassScriptPhysician profile
Joseph P Corallo
NPI 1073766804
$97,486.52
in general payments reported to CMS, 2019-2025
26 companies · $53K in 2025
The $53K reported for 2025 was more than what 98% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.85 · 2020: $3,028 · 2021: $6,251 · 2022: $3,968 · 2023: $3,127 · 2024: $28K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $58K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,500 · Travel and Lodging: $8,623 · Food and Beverage: $8,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $57,904.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,500.00 |
| Travel and Lodging | $8,622.53 |
| Food and Beverage | $8,166.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $94,563.75 | 2020-2025 | Da Vinci Surgical System |
| Davol INC. | $833.84 | 2021-2025 | Phasix Mesh |
| Biotissue Holdings INC. | $220.34 | 2022-2023 | |
| Boston Scientific Corporation | $208.63 | 2022-2025 | Axonics |
| Innovation Technologies INC | $188.15 | 2024 | Irrisept |
| Kerecis Limited | $159.22 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Zimmer Biomet Holdings, INC. | $153.13 | 2023 | Ribfix Blu Advantage |
| Tela Bio, INC. | $149.72 | 2022 | |
| Solventum Corporation | $133.89 | 2025 | Abthera Advance, V.A.C. Veraflo Cleanse Choice |
| Organogenesis INC. | $122.71 | 2022 | |
| W. L. Gore & Associates, INC. | $107.95 | 2023 | Gore Enform Preperitoneal Biomaterial |
| Medtronic, INC. | $107.41 | 2023-2025 | Interstim |
| Ethicon US, LLC | $101.23 | 2020-2025 | Enseal X1, Echelon; Endopath, Proximate |
| Conmed Corporation | $80.00 | 2022 | |
| Aroa Biosurgery Incorporated | $70.36 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $45.11 | 2023-2024 | Axonics |
| Acera Surgical, INC. | $36.13 | 2024-2025 | Restrata Wound Matrix |
| Kowa Pharmaceuticals America, INC. | $32.46 | 2022-2023 | Seglentis |
| Merck Sharp & Dohme LLC | $30.16 | 2019 | |
| Access Pro Medical, LLC | $27.13 | 2025 | Matriderm |
| Hologic Sales and Service, LLC | $23.47 | 2024 | Coolseal Generator |
| Lexington Medical, INC. | $20.68 | 2023 | Aeon Endostapler & Echelon Flex Powered Stapler |
| Cumberland Pharmaceuticals, INC. | $20.41 | 2025 | Caldolor |
| Heron Therapeutics, INC. | $18.19 | 2023 | Zynrelef |
| Kci USA, INC. | $16.69 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $15.76 | 2025 | Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Corallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.